CA2724413C - Compositions et procedes ayant trait aux composes activant le facteur de transcription de choc thermique et cibles correspondantes - Google Patents

Compositions et procedes ayant trait aux composes activant le facteur de transcription de choc thermique et cibles correspondantes Download PDF

Info

Publication number
CA2724413C
CA2724413C CA2724413A CA2724413A CA2724413C CA 2724413 C CA2724413 C CA 2724413C CA 2724413 A CA2724413 A CA 2724413A CA 2724413 A CA2724413 A CA 2724413A CA 2724413 C CA2724413 C CA 2724413C
Authority
CA
Canada
Prior art keywords
agents
disease
hsf1
compound
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2724413A
Other languages
English (en)
Other versions
CA2724413A1 (fr
Inventor
Dennis J. Thiele
Daniel W. Neef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CA2724413A1 publication Critical patent/CA2724413A1/fr
Application granted granted Critical
Publication of CA2724413C publication Critical patent/CA2724413C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés activant le HSF, des procédés pour leur découverte, et leur recherche et leurs utilisations thérapeutiques. En particulier, la présente invention concerne des composés capables de faciliter lactivation du HSFl, et des procédés destinés à utiliser de tels composés en tant quagents thérapeutiques afin de traiter plusieurs états pathologiques associés au mauvais repliement des protéines.
CA2724413A 2008-05-15 2009-05-15 Compositions et procedes ayant trait aux composes activant le facteur de transcription de choc thermique et cibles correspondantes Active CA2724413C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5351308P 2008-05-15 2008-05-15
US61/053,513 2008-05-15
PCT/US2009/044186 WO2009140621A2 (fr) 2008-05-15 2009-05-15 Compositions et procédés ayant trait aux composés activant le facteur de transcription de choc thermique et cibles correspondantes

Publications (2)

Publication Number Publication Date
CA2724413A1 CA2724413A1 (fr) 2009-11-19
CA2724413C true CA2724413C (fr) 2016-10-18

Family

ID=41319361

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724413A Active CA2724413C (fr) 2008-05-15 2009-05-15 Compositions et procedes ayant trait aux composes activant le facteur de transcription de choc thermique et cibles correspondantes

Country Status (4)

Country Link
EP (1) EP2300004A4 (fr)
CN (1) CN102088973A (fr)
CA (1) CA2724413C (fr)
WO (1) WO2009140621A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
ES2557465T3 (es) * 2010-03-17 2016-01-26 Taivex Therapeutics Inc. Moduladores de la actividad de HEC 1 y procedimientos para ello
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
CN104395752B (zh) 2011-11-21 2017-09-15 泰纬生命科技股份有限公司 对hec1活性调节剂具有反应的癌症的生物标记
RU2019101889A (ru) 2013-03-15 2019-03-28 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
JP6479749B2 (ja) 2013-03-15 2019-03-06 ヴァーセオン コーポレイション トロンビン阻害剤としてのハロゲノピラゾール
WO2015143653A1 (fr) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2016044662A1 (fr) 2014-09-17 2016-03-24 Verseon Corporation Composés de pyridone substituée par pyrazolyl en tant qu'inhibiteurs de sérine protéase
EP3261639B1 (fr) 2015-02-27 2022-08-24 Verseon International Corporation Composés pyrazole substitués à utiliser en tant qu'inhibiteurs de sérine protéase
US11028061B2 (en) * 2015-07-27 2021-06-08 Sanford Burnham Prebys Medical Discovery Institute Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
CN105524056A (zh) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 一种氨基噻唑化合物及其制备方法和应用
CN107519239A (zh) * 2017-04-25 2017-12-29 兰州大学 黄芩提取物在制备激活hsp70药物中的应用
WO2019241376A1 (fr) * 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Traitement de troubles cognitifs à l'aide de nitazoxanide (ntz), d'analogues de nitazoxanide (ntz) et de leurs métabolites
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
CA3115830C (fr) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Composes pour inhibition de l'integrine .alpha.4.beta.7
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR20210121186A (ko) 2019-01-31 2021-10-07 화이자 인코포레이티드 Cdk2에 대한 억제 활성을 갖는 3-카본일아미노-5-사이클로펜틸-1h-피라졸 화합물
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
CN113087783B (zh) * 2021-04-20 2021-10-01 南京医科大学 Hd治疗药物中的小分子多肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410348A (pt) * 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
MXPA06002567A (es) * 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
WO2005041879A2 (fr) * 2003-10-28 2005-05-12 Pharmacia Corporation Association de l'inhibiteur de hsp90 et de l'inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie
WO2005044194A2 (fr) * 2003-10-28 2005-05-19 Pharmacia Corporation Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90
EP1791822A1 (fr) * 2004-08-05 2007-06-06 F.Hoffmann-La Roche Ag Aminothiazoles substitués n-acyle-2-
US7919603B2 (en) * 2005-12-19 2011-04-05 New York University Heat shock RNA

Also Published As

Publication number Publication date
EP2300004A4 (fr) 2012-05-30
WO2009140621A3 (fr) 2010-02-25
WO2009140621A8 (fr) 2011-05-12
CN102088973A (zh) 2011-06-08
WO2009140621A2 (fr) 2009-11-19
EP2300004A2 (fr) 2011-03-30
CA2724413A1 (fr) 2009-11-19

Similar Documents

Publication Publication Date Title
CA2724413C (fr) Compositions et procedes ayant trait aux composes activant le facteur de transcription de choc thermique et cibles correspondantes
US9718784B2 (en) Substituted pyrazoles as heat shock transcription factor activators
US10526297B2 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
JP2014533721A (ja) 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用
JP5431485B2 (ja) β−アミロイド疾患およびシヌクレイノパチーを処置するための化合物、組成物、および方法
TW200911237A (en) Drug combinations for the treatment of duchenne muscular dystrophy
WO2008119238A1 (fr) Composés hétérocycliques substitués à cinq éléments, leur méthode de préparation et leur utilisation en médecine
US20170227553A1 (en) Compositions and methods for identifying and treating conditions involving hsf1 activity
EP2888252B1 (fr) Composés de benzofurazane anti-amyloïdes et procédés s'y rapportant
EP2830608B1 (fr) Dérivés de phénylurée et de phénylcarbamate comme inhibiteurs d'agrégation de protéine
CN110234643A (zh) RORγ调节剂及其用途
JP2015526419A (ja) ミネラルコルチコイド受容体拮抗薬
US20220267308A1 (en) Modulators of Excitatory Amino Acid Transporters and Methods Using Same
DE60110802T2 (de) Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
AU2011326130B9 (en) Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
JP2014532656A (ja) 炎症および免疫関連用途のための化合物
CA3148602A1 (fr) Medicaments a petites molecules et procedes associes pour le traitement des maladies liees au tdp-43, a l'alpha-synucleine, a la proteine huntingtin et a la formation d'oligomeres de la proteine tau
JP2010502680A (ja) ミトコンドリアナトリウム−カルシウムエクスチェンジャーとして有用な環状スルホン

Legal Events

Date Code Title Description
EEER Examination request